Skip to main content
letter
. 2024 Nov 1;10:75. doi: 10.1186/s40959-024-00275-5

Fig. 2.

Fig. 2

Cumulative incidence of Major Adverse Cardiac Events in a matched cohort of patients with AML treated with venetoclax or anthracyclines. Central Illustration. Major Adverse Cardiac Events in Patients with AML treated with anthracyclines or venetoclax. (Left) Flowchart and outcomes of the study. (Right) Cumulative incidence curve of MACE in a matched cohort of patients treated with venetoclax or anthracyclines